PRAX
NASDAQPraxis Precision Medicines Inc.
News · 26 weeks570%
2026-03-012026-08-23
Mix3190d
- Insider10(32%)
- Other9(29%)
- SEC Filings8(26%)
- Analyst2(6%)
- Earnings1(3%)
- Offering1(3%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Praxis Precision Medicines Inc.SCHEDULE 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)
- SECSEC Form 10-Q filed by Praxis Precision Medicines Inc.10-Q - Praxis Precision Medicines, Inc. (0001689548) (Filer)
- SECPraxis Precision Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Praxis Precision Medicines, Inc. (0001689548) (Filer)
- PRPraxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial ResultsMid-cycle meeting completed for ulixacaltamide HCl; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of January 29, 2027 Mid-cycle meeting completed for relutrigine; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of December 27, 2026 FDA Bioresearch Monitoring (BIMO) inspections of Praxis for both ulixacaltamide and relutrigine completed with no Form FDA 483 observations Commercial infrastructure build-out accelerating for ulixacaltamide HCl in Essential Tremor and relutrigine in SCN2A and SCN8A developmental and epileptic en
- PRPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on August 3, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 7,318 shares of its common stock to twenty-nine new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4)
- PRPraxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026BOSTON, July 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the second quarter ended June 30, 2026 and provide a corporate update, before the financial markets open on Thursday, August 6, 2026. The Company will host a conference call and a live webcast to review the second quarter financial results and provide a corporate update on Thursday, August 6, 2026, at 8:30 am ET, which can be accessed by visiting this registration link. The live webcast will also be available through the Events & Presentat
- ANALYSTGoldman initiated coverage on Praxis Precision Medicines with a new price targetGoldman initiated coverage of Praxis Precision Medicines with a rating of Buy and set a new price target of $447.00
- INSIDERChief Executive Officer Souza Marcio gifted 23,121 shares, decreasing direct ownership by 27% to 56,495 units (SEC Form 4)4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)
- SECPraxis Precision Medicines Inc. filed SEC Form 8-K: Other Events8-K - Praxis Precision Medicines, Inc. (0001689548) (Filer)
- PRPraxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential TremorCollaboration aims to quickly enable ulixacaltamide to be delivered via active transdermal route Potential to expand the addressable market for ulixacaltamide beyond the initial patient population and to enable additional life-cycle management opportunities Praxis to make equity investment in Remagine Labs, accelerating the companies' collaboration BOSTON, Mass. and AUSTIN, Texas, July 07, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated central nervous system (CNS) precision neuroscience biopharmaceutical company, and Remagine Labs, Inc., a developer of electronically controlled transdermal drug delivery systems, today announc
- SECPraxis Precision Medicines Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - Praxis Precision Medicines, Inc. (0001689548) (Filer)
- PRPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on July 1, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 951 shares of its common stock to five new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4). The 2024
- SECPraxis Precision Medicines Inc. filed SEC Form 8-K: Other Events8-K - Praxis Precision Medicines, Inc. (0001689548) (Filer)
- PRPraxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic EncephalopathiesFDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) notified Praxis that it has extended by three months the review period for its New Drug Application (NDA) for relutrigine for the treatment of SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs), setting an updated PDUFA target action date from September 27, 2026 to December 27, 2026. The extension follows Praxis's submission of additional sensitivity analyses of exis
- INSIDERDirector Desimone Jill exercised 11,600 shares at a strike of $71.20 and sold $3,611,335 worth of shares (11,600 units at $311.32) as part of a pre-agreed trading plan (SEC Form 4)4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)
- SECPraxis Precision Medicines Inc. filed SEC Form 8-K: Other Events8-K - Praxis Precision Medicines, Inc. (0001689548) (Filer)
- PRPraxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function VariantsThe Breakthrough Therapy Designation (BTD) was granted based on the positive results from the EMBRAVE Part A trial of elsunersen Elsunersen demonstrated a 77% sham-adjusted reduction in monthly seizures (p=0.015), with benefit sustained in the open-label extension for up to one year The pivotal EMBRAVE3 study is enrolling under a streamlined, single-arm registrational pathway aligned with the FDA Elsunersen now holds Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease Designations from the FDA, and Orphan Drug and PRIME designations from the EMA BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervou
- ANALYSTRBC Capital Mkts initiated coverage on Praxis Precision Medicines with a new price targetRBC Capital Mkts initiated coverage of Praxis Precision Medicines with a rating of Outperform and set a new price target of $449.00
- INSIDERDirector Arbuckle Stuart A was granted 1,371 shares, increasing direct ownership by 118% to 2,537 units (SEC Form 4)4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)
- INSIDERDirector Chodakewitz Jeffrey was granted 1,371 shares (SEC Form 4)4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)
- INSIDERDirector Young William D was granted 1,371 shares, increasing direct ownership by 72% to 3,269 units (SEC Form 4)4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)
- INSIDERDirector Cudkowicz Merit Ester was granted 1,371 shares (SEC Form 4)4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)
- INSIDERDirector Desimone Jill was granted 1,371 shares, increasing direct ownership by 142% to 2,337 units (SEC Form 4)4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)
- INSIDERDirector Kindler Jeffrey B was granted 1,371 shares, increasing direct ownership by 118% to 2,537 units (SEC Form 4)4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)
- INSIDERDirector Mitchell Dean J was granted 1,371 shares, increasing direct ownership by 8% to 18,622 units (SEC Form 4)4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)
PRAX FAQ
7 questionsWhat does Praxis Precision Medicines Inc. do?
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562...Where does PRAX stock trade?
Praxis Precision Medicines Inc. (PRAX) is listed on NASDAQ.What sector and industry is PRAX in?
Praxis Precision Medicines Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Praxis Precision Medicines Inc. go public?
Praxis Precision Medicines Inc. (PRAX) completed its IPO in 2020.What are analysts saying about PRAX?
Praxis Precision Medicines Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Buy on 2026-07-13.What companies are similar to PRAX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PRAX side-by-side with any of them on Quantisnow.How can I track PRAX on Quantisnow?
Quantisnow aggregates Praxis Precision Medicines Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PRAX to receive live email and push alerts on every new disclosure.